|
|
Volumn 6, Issue 7, 2007, Pages 505-506
|
|
Diabetes drugs under scrutiny in a post-Vioxx world
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
INSULIN SENSITIZING AGENT;
PIOGLITAZONE;
ROFECOXIB;
ROSIGLITAZONE;
ARTICLE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG LABELING;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEART DEATH;
HEART INFARCTION;
HEART MUSCLE ISCHEMIA;
HUMAN;
ONLINE SYSTEM;
OUTCOMES RESEARCH;
PHARMACEUTICAL CARE;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
UNITED STATES;
HUMANS;
HYPOGLYCEMIC AGENTS;
THIAZOLIDINEDIONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 34347407541
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2371 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
